Ultragenyx Pharmaceutical - RARE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $111.58
  • Forecasted Upside: 170.37 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$41.27
▲ +0.98 (2.43%)

This chart shows the closing price for RARE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ultragenyx Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RARE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RARE

Analyst Price Target is $111.58
▲ +170.37% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $111.58, with a high forecast of $142.00 and a low forecast of $60.00. The average price target represents a 170.37% upside from the last price of $41.27.

This chart shows the closing price for RARE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Ultragenyx Pharmaceutical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/6/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/3/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/1/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/1/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings
6/30/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2022Evercore ISILower Target$60.00Low
8/3/2022CitigroupLower Target$146.00 ➝ $142.00Low
7/29/2022BarclaysLower Target$141.00 ➝ $105.00Low
7/28/2022Piper SandlerLower TargetOverweight$135.00 ➝ $130.00Low
7/1/2022Stifel NicolausLower TargetBuy$176.00 ➝ $142.00Low
5/24/2022The Goldman Sachs GroupLower TargetNeutral$139.00 ➝ $101.00Low
5/18/2022Piper SandlerLower TargetOverweight$170.00 ➝ $135.00Medium
5/6/2022CowenLower Target$124.00 ➝ $99.00High
5/6/2022CowenLower Target$124.00 ➝ $99.00High
3/16/2022Credit Suisse GroupUpgradeNeutral ➝ Outperform$99.00 ➝ $105.00High
2/11/2022Morgan StanleyLower TargetOverweight$120.00 ➝ $118.00High
2/11/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$132.00Low
2/1/2022Morgan StanleyLower TargetOverweight$156.00 ➝ $120.00High
10/5/2021SVB LeerinkReiterated RatingBuyMedium
9/30/2021HC WainwrightInitiated CoverageBuy$106.00High
8/19/2021UBS GroupInitiated CoverageSell$73.00Medium
8/3/2021WedbushLower TargetNeutral$106.00 ➝ $91.00High
8/3/2021BarclaysLower TargetOverweight$178.00 ➝ $141.00High
7/15/2021GuggenheimInitiated CoverageNeutral$84.74Low
6/29/2021Bank of AmericaUpgradeNeutral ➝ Buy$162.00High
5/9/2021SVB LeerinkInitiated CoverageBuy$178.00High
5/6/2021CitigroupUpgradeNeutral ➝ Buy$160.00 ➝ $151.00High
5/5/2021Evercore ISIUpgradeIn-Line ➝ Outperform$144.00High
5/5/2021Morgan StanleyLower TargetOverweight$170.00 ➝ $156.00Low
4/19/2021Morgan StanleyLower TargetOverweight$175.00 ➝ $170.00Medium
3/1/2021Stifel NicolausInitiated CoverageBuy$179.00High
2/16/2021SVB LeerinkBoost TargetOutperform$115.00 ➝ $178.00Low
2/12/2021WedbushBoost TargetNeutral$113.00 ➝ $130.00Low
2/12/2021Piper SandlerBoost TargetOverweight$165.00 ➝ $170.00Low
2/12/2021BarclaysBoost TargetOverweight$176.00 ➝ $186.00Low
2/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$165.00Low
1/25/2021Credit Suisse GroupBoost TargetNeutral$64.00 ➝ $99.00High
1/11/2021Robert W. BairdBoost TargetOutperform$110.00 ➝ $165.00Medium
1/11/2021BarclaysBoost TargetOverweight$121.00 ➝ $176.00High
12/7/2020WedbushDowngradeOutperform ➝ Neutral$105.00 ➝ $110.00Medium
11/24/2020Evercore ISIReiterated RatingIn-Line$110.00High
11/12/2020Bank of AmericaDowngradeBuy ➝ Neutral$104.00 ➝ $126.00High
10/28/2020Truist FinancialBoost Target$88.00 ➝ $110.00High
10/28/2020WedbushBoost TargetOutperform$97.00 ➝ $105.00Low
10/28/2020Morgan StanleyBoost TargetOverweight$89.00 ➝ $91.00Low
10/28/2020BarclaysBoost TargetOverweight$99.00 ➝ $121.00Medium
10/28/2020SVB LeerinkBoost TargetOutperform$110.00 ➝ $115.00Medium
10/27/2020Piper SandlerBoost TargetOverweight$83.00 ➝ $108.00Medium
10/15/2020Bank of AmericaBoost TargetBuy$93.00 ➝ $107.00Medium
10/13/2020Morgan StanleyBoost TargetOverweight$87.00 ➝ $89.00Medium
7/31/2020Credit Suisse GroupReiterated RatingHold$64.00Low
7/31/2020Morgan StanleyLower TargetOverweight$88.00 ➝ $87.00High
7/31/2020BarclaysBoost TargetOverweight$87.00 ➝ $99.00Low
7/28/2020JPMorgan Chase & Co.Reiterated RatingBuy$84.00High
7/15/2020Morgan StanleyBoost TargetOverweight$83.00 ➝ $88.00Low
7/1/2020SunTrust BanksBoost Target$82.00 ➝ $88.00Medium
7/1/2020Credit Suisse GroupBoost TargetNeutral$60.00 ➝ $64.00High
7/1/2020JPMorgan Chase & Co.Boost TargetOverweight$76.00 ➝ $84.00High
7/1/2020WedbushBoost TargetHold ➝ Outperform$83.00 ➝ $91.00High
7/1/2020Morgan StanleyBoost TargetOverweight$79.00 ➝ $83.00High
7/1/2020Robert W. BairdBoost TargetOutperform$75.00 ➝ $90.00High
6/30/2020Piper SandlerBoost TargetOverweight$70.00 ➝ $83.00High
6/19/2020SunTrust BanksBoost TargetBuy$80.00 ➝ $82.00High
6/19/2020WedbushBoost TargetOutperform$73.00 ➝ $83.00High
5/18/2020Stifel NicolausBoost TargetPositive ➝ Buy$70.00 ➝ $82.00High
5/8/2020CitigroupBoost TargetNeutral$53.00 ➝ $66.00Low
4/1/2020Robert W. BairdReiterated RatingBuy$75.00High
2/18/2020Evercore ISIReiterated RatingBuyLow
2/16/2020JPMorgan Chase & Co.Reiterated RatingBuy$76.00Low
2/14/2020WedbushBoost TargetOutperform$71.00 ➝ $75.00High
2/14/2020CowenReiterated RatingBuy$75.00High
1/17/2020Morgan StanleyBoost TargetOverweight$73.00 ➝ $77.00Low
1/10/2020SunTrust BanksReiterated RatingBuy$75.00 ➝ $80.00High
1/2/2020Raymond JamesDowngradeOutperform ➝ Market PerformHigh
12/18/2019Piper Jaffray CompaniesReiterated RatingBuy$70.00High
12/18/2019CowenReiterated RatingBuy$59.00High
12/17/2019Morgan StanleyLower TargetOverweight$76.00 ➝ $73.00Medium
11/6/2019Morgan StanleyLower TargetOverweight$79.00 ➝ $76.00High
11/6/2019JPMorgan Chase & Co.Reiterated RatingBuy$75.00High
11/5/2019CowenReiterated RatingBuy$62.00High
9/4/2019Piper Jaffray CompaniesSet TargetBuy$75.00Low
9/4/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
9/4/2019SVB LeerinkReiterated RatingOutperform ➝ Positive$80.00 ➝ $85.00High
8/15/2019WedbushReiterated RatingBuy$75.00High
8/15/2019CowenReiterated RatingBuyHigh
8/5/2019JPMorgan Chase & Co.Reiterated RatingBuy$75.00Medium
8/4/2019BarclaysReiterated RatingBuy$87.00Medium
8/2/2019Morgan StanleyLower TargetOverweight$83.00 ➝ $79.00High
8/2/2019WedbushReiterated RatingOutperform ➝ Outperform$75.00High
6/17/2019Morgan StanleySet TargetBuy$83.00Low
5/9/2019BarclaysReiterated RatingBuyLow
5/7/2019WedbushReiterated RatingOutperform$88.00 ➝ $77.00High
3/27/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$68.00 ➝ $83.00Medium
2/26/2019CowenReiterated RatingBuy$69.00High
2/22/2019Raymond JamesReiterated RatingOutperform ➝ Outperform$80.00Low
2/21/2019CitigroupBoost TargetNeutral ➝ Neutral$54.00 ➝ $62.00High
2/20/2019Credit Suisse GroupReiterated RatingHold$59.00High
1/23/2019SunTrust BanksBoost TargetBuy$71.00High
1/7/2019WedbushReiterated RatingOutperform$88.00Medium
1/7/2019CowenReiterated RatingBuyMedium
1/4/2019Credit Suisse GroupSet TargetHold$59.00Medium
1/2/2019Raymond JamesDowngradeOutperform ➝ Market PerformMedium
11/15/2018Credit Suisse GroupSet TargetHold$59.00High
11/14/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
11/8/2018CitigroupUpgradeSell ➝ Neutral$46.00 ➝ $54.00N/A
11/6/2018Raymond JamesBoost TargetOutperform ➝ Buy$53.00 ➝ $57.00Medium
10/29/2018WedbushLower TargetOutperform ➝ Outperform$90.00 ➝ $88.00High
10/29/2018CitigroupLower TargetSell ➝ Sell$49.00 ➝ $46.00High
10/29/2018Morgan StanleySet TargetHold$92.00 ➝ $70.00High
10/29/2018Credit Suisse GroupLower TargetNeutral ➝ Hold$78.00 ➝ $59.00High
10/29/2018SunTrust BanksLower TargetBuy ➝ Buy$83.00 ➝ $54.00Medium
10/27/2018JPMorgan Chase & Co.Set TargetBuy$68.00Medium
10/26/2018Raymond JamesSet TargetBuy$70.00Low
10/26/2018Piper Jaffray CompaniesLower TargetOverweight$70.00High
10/7/2018JPMorgan Chase & Co.Reiterated RatingBuy$86.00Low
9/11/2018Bank of AmericaBoost TargetBuy ➝ Buy$72.00 ➝ $94.00Low
9/10/2018Morgan StanleyReiterated RatingEqual ➝ Equal Weight$92.00Low
9/2/2018JMP SecuritiesReiterated RatingBuy$94.00Medium
8/30/2018WedbushBoost TargetOutperform ➝ Outperform$80.00 ➝ $90.00Medium
8/29/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
8/20/2018SunTrust BanksBoost TargetBuy ➝ Positive$83.00Low
8/6/2018WedbushBoost TargetOutperform ➝ Outperform$71.00 ➝ $80.00High
8/3/2018Robert W. BairdReiterated RatingBuy$95.00High
8/3/2018BarclaysReiterated RatingOverweight ➝ Overweight$74.00 ➝ $92.00High
8/3/2018Piper Jaffray CompaniesBoost TargetOverweight$85.00High
7/17/2018SVB LeerinkBoost TargetOutperform ➝ Outperform$68.00 ➝ $95.00Low
6/21/2018Credit Suisse GroupDowngradeOutperform ➝ Neutral$67.00 ➝ $80.00High
5/11/2018BarclaysUpgradeEqual Weight ➝ Overweight$62.00 ➝ $74.00High
5/10/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$63.00Medium
4/18/2018CowenReiterated RatingBuyMedium
4/18/2018Stifel NicolausBoost TargetBuy ➝ Buy$74.00 ➝ $77.00High
4/18/2018WedbushReiterated RatingOutperform ➝ Positive$64.00 ➝ $71.00High
4/18/2018JMP SecuritiesBoost TargetOutperform$70.00 ➝ $74.00High
4/18/2018SunTrust BanksUpgradeHold ➝ Buy$41.67 ➝ $55.00Low
4/17/2018Bank of AmericaBoost Target$61.00 ➝ $72.00Low
3/22/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$67.00Medium
2/23/2018Robert W. BairdReiterated RatingBuy$70.00Medium
2/21/2018Bank of AmericaBoost TargetBuy ➝ Buy$60.00 ➝ $61.00High
2/21/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$57.00 ➝ $60.00High
2/21/2018JPMorgan Chase & Co.Reiterated RatingMarket Outperform ➝ Overweight$68.00 ➝ $66.00High
2/21/2018Stifel NicolausReiterated RatingBuy ➝ Buy$85.00 ➝ $74.00High
1/22/2018Evercore ISIUpgradeIn-Line ➝ OutperformHigh
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$67.00Low
12/15/2017Raymond JamesReiterated RatingBuyLow
12/5/2017Raymond JamesReiterated RatingBuyMedium
12/5/2017BarclaysBoost TargetEqual Weight ➝ Equal Weight$60.00 ➝ $62.00High
12/4/2017Jefferies Financial GroupUpgradeHold ➝ Buy$58.00 ➝ $72.00High
11/15/2017CowenReiterated RatingBuyN/A
11/5/2017JPMorgan Chase & Co.Reiterated RatingBuy$76.00N/A
11/3/2017Robert W. BairdLower TargetOutperform$85.00 ➝ $80.00N/A
10/6/2017Morgan StanleyReiterated RatingEqual Weight$69.00 ➝ $71.00N/A
(Data available from 9/28/2017 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/2/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/1/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
5/31/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
6/30/2022
  • 5 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/30/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/29/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2022

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Ultragenyx Pharmaceutical logo
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Read More

Today's Range

Now: $41.27
Low: $40.56
High: $41.64

50 Day Range

MA: $48.79
Low: $39.96
High: $55.77

52 Week Range

Now: $41.27
Low: $39.75
High: $91.10

Volume

732,630 shs

Average Volume

564,463 shs

Market Capitalization

$2.89 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Ultragenyx Pharmaceutical?

The following equities research analysts have issued reports on Ultragenyx Pharmaceutical in the last twelve months: Barclays PLC, Citigroup Inc., Cowen Inc, Cowen Inc., Credit Suisse Group AG, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for RARE.

What is the current price target for Ultragenyx Pharmaceutical?

12 Wall Street analysts have set twelve-month price targets for Ultragenyx Pharmaceutical in the last year. Their average twelve-month price target is $111.58, suggesting a possible upside of 170.4%. Stifel Nicolaus has the highest price target set, predicting RARE will reach $142.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $60.00 for Ultragenyx Pharmaceutical in the next year.
View the latest price targets for RARE.

What is the current consensus analyst rating for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RARE will outperform the market and that investors should add to their positions of Ultragenyx Pharmaceutical.
View the latest ratings for RARE.

What other companies compete with Ultragenyx Pharmaceutical?

How do I contact Ultragenyx Pharmaceutical's investor relations team?

Ultragenyx Pharmaceutical's physical mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company's listed phone number is (415) 483-8800 and its investor relations email address is [email protected] The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com. Learn More about contacing Ultragenyx Pharmaceutical investor relations.